CClinicalTrials.gg
Sign In
RecruitingNCT04226612Updated Jan 13, 2020

Association of Inpatient Blood Pressure Levels With In-hospital Adverse Events(APPLE Study)

An observational study in Blood Pressure, sponsored by Guangdong Provincial People's Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2020-01-13.

Sponsored by Guangdong Provincial People's Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2019, 6 years 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2000; still recruiting 26 years 9 months later.
Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
100,000
Sex
All
01

Study summary

The purpose of the study is to investigate the association between inpatient blood pressure levels and in-hosopital adverse outcomes.

Read the detailed description

Study population includes subjects who are hospitalized due to illness, of any race or ethnicity, any of age.The primary outcome is all-cause mortality occured in the hospital.

02

Conditions studied

  • Blood Pressure

Keywords

  • Blood Pressure
  • Inpatient
  • Adverse Events
  • All-cause mortality
03

In context

Lead sponsor

Guangdong Provincial People's Hospital is the lead sponsor of 231 studies on the registry; 101 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Inpatient

Inclusion criteria

  • Inpatient with all age or race;
  • Have blood pressure data.

Exclusion criteria

Exclusion Criteria:

  • Non-patients；
  • Death outside the hospital；
  • Missing blood pressure data.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
100,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. All-cause mortality

    All-cause mortality was confirmed through a combination of hospital medical records.

    Time frame: during the procedure

07

Study locations

1 of 1 sites recruiting
  • Feng Ying-qing
    Guangzhou, Guangdong 510080, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04226612
Lead sponsor
Guangdong Provincial People's Hospital
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Jan 1, 2000
Primary completion
Dec 31, 2019 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jan 13, 2020

Study contacts

Feng Ying-qing, PhD
Contact
651792209@qq.com
+862083827812
Feng Ying-qing, PhD
study director · Guangdong Provincial People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Guangdong Provincial People's Hospital

Start the discussion